Portola Pharmaceuticals

Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies.[2]

Portola Pharmaceuticals
TypePublic[1]
IndustryPharmaceuticals
FateAcquired by Alexion Pharmaceuticals
Founded2003
FoundersCharles J. Homcy, David R. Philips
HeadquartersSouth San Francisco, California, United States
Area served
Worldwide
Key people
Scott Garland (CEO)[1]
ProductsAndexxa
Bevyxxa
Cerdulatinib
Revenue$ 40,130 (2018)[1]
Number of employees
324 (2018)[1]
SubsidiariesPortola Pharma UK Limited
Websiteportola.com

Headquartered and founded in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index.

In May 2020, Alexion Pharmaceuticals and Portola announced that they have entered into a definitive merger agreement for Alexion to acquire Portola.[3]

History

The company was founded on September, 2, 2003 and named after Gaspar de Portolà, who was the first european to see San Francisco Bay. It completed IPO on NASDAQ in May 2013.

The company developed P2Y12 inhibitor Elinogrel transferring rights to Novartis in 2009.[4] The rights were returned to Portola in 2012, which decided not to continue development.

Currently Portola Pharmaceuticals has collaboration agreements with SRX Cardio, Dermavant, Millennium Pharmaceuticals, Daiichi Sankyo, Bayer, Janssen, BMS and Pfizer.[5]

Products

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.